Currently, most of the available therapies for tauopathies such as AD approved by regulatory agencies like the United States Food and Drugs Administration (FDA), European Medicines Agency, and Pharmaceuticals and Medical Devices Agency employ the use of acetylcholine esterase inhibitors and N-methyl-D-aspartate receptor antagonists to treat mild to severe AD [13]. This evidence concerns the gene ACHE and Alzheimer disease.